University of Connecticut researchers found that a two-drug anti-aging combination caused severe brain damage in laboratory mice [1].

The findings raise significant safety concerns regarding senolytic therapies, which are designed to clear aged cells from the body to potentially extend healthspan. If these neurotoxic effects translate to humans, the therapy could cause irreversible neurological harm.

The study focused on a combination of two drugs: dasatinib and quercetin [1]. According to the research, this specific pairing resulted in extensive loss of myelin, the protective sheath that covers nerve fibers in the brain [1]. Researchers observed cellular changes that resemble those found in multiple sclerosis, a chronic disease that affects the central nervous system [1].

The research team published their findings on March 16, 2026 [2], in the Proceedings of the National Academy of Sciences. The study was conducted in the U.S. using laboratory mice to observe how the senolytic treatment interacted with brain tissue over time [1].

While senolytics are often promoted as a way to combat age-related decline, this study suggests that the process of removing senescent cells may have unintended consequences. The researchers said that the therapy may have neurotoxic effects that could outweigh the benefits of anti-aging treatment [1].

This discovery prompts a call for greater caution before such combinations move into widespread clinical use. The University of Connecticut team said there is a need to understand why this specific combination targets myelin-producing cells, which are essential for healthy brain function [1].

“The therapy could cause irreversible neurological harm.”

This study highlights a critical risk in the development of senolytic medicine, suggesting that the systemic removal of 'zombie cells' may not be universally beneficial. Because the damage observed in mice mimics the myelin degradation seen in multiple sclerosis, it indicates that these drugs may inadvertently attack the brain's infrastructure, potentially turning an anti-aging treatment into a catalyst for neurodegenerative disease.